Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCND2 | P30279 | 1/20 | 0.31 |
| ▸ | CCND3 | P30281 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054887 | 0.92 | FGFR1 (0.38) | FGFR1KDRLCKJAK3MAPK14 | |
| SCHEMBL5060059 | 0.91 | FGFR1 (0.40) | FGFR1MAPK14RAF1BRAFEGFR | |
| SCHEMBL5052198 | 0.91 | FGFR1 (0.38) | FGFR1KDRLCKJAK3MAPK14 | |
| SCHEMBL5052186 | 0.90 | BRAF (0.40) | FGFR1KDRMAPK14RAF1BRAF | |
| SCHEMBL5054864 | 0.90 | CDK4 (0.38) | FGFR1KDRLCKJAK3MAPK14 | |
| SCHEMBL5062750 | 0.89 | IGF1R (0.37) | FGFR1KDRLCKJAK3MAPK14 | |
| SCHEMBL5054969 | 0.89 | KDR (0.38) | FGFR1KDRLCKJAK3MAPK14 | |
| SCHEMBL5062384 | 0.87 | FGFR1 (0.35) | FGFR1KDRLCKJAK3MAPK14 | |
| SCHEMBL5060234 | 0.86 | KDR (0.34) | FGFR1KDRLCKJAK3MAPK14 | |
| SCHEMBL5052101 | 0.86 | NTRK1 (0.38) | FGFR1KDRLCKJAK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | FGFR1 184/4885KDR 41/4885LCK 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.